euro adhoc: Intercell AG / other / sanofi pasteur exercises option on Intercell’s bacterial vaccine antigens - up to EUR 23 m license and milestone payments (E)

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

01.07.2005

Vienna - July 1, 2005 - Intercell AG (VSE - "ICLL") today announced that its
partner sanofi pasteur S.A. (previously aventis pasteur S.A.), the vaccines
business of the sanofi-aventis group, exercised its option on exclusive
worldwide commercial rights on certain bacterial vaccine antigens, which have
been identified by Intercell’s Antigen Identification Program under a
Collaboration and License Option Agreement the parties concluded in December
2003.

The option exercise will trigger license fees and recognition of previously
unearned research funding and success fees resulting in an aggregate value of
about EUR 3 million. Over the entire term of the agreement Intercell will be
entitled to further milestone based license payments totaling to about EUR 20
million, as well as royalties on future net sales.

"Our partner sanofi pasteur is a leader and innovator in the field of vaccines
and we are delighted that our Antigen Identification Program has again
successfully delivered attractive vaccine antigens for another important
bacterial indication with a high unaddressed medical need," states Intercell’s
Chief Operating Officer, Gerd Zettlmeissl.

"Intercell’s Antigen Identification Program is a very promising new technology
for the field of vaccine development", commented Michel DeWilde, Executive
Vice-president, Research and Development at sanofi pasteur. "We are impressed
with the excellent progress Intercell has made in this important project."

About Intercell AG
Intercell AG is a fast growing biotechnology company focusing on the design and
development of novel vaccines for prevention and treatment of diseases with
substantial unaddressed medical need. The Company’s unique position is based on
the combination of antigens and immunizers (adjuvants) derived from its
proprietary technology platforms and its in-house GMP manufacturing facilities.
Intercell’s technology has been endorsed by collaborative agreements with a
number of global pharmaceutical companies, including sanofi pasteur, Merck&Co.,
Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad
development pipeline with a vaccine for Japanese Encephalitis about to enter
Phase III, a vaccine for Hepatitis C undergoing Phase II trials, and five
products focused on infectious diseases in the pre-clinical phase. Intercell is
listed on the Vienna stock exchange under the symbol "ICLL".
For more information please visit: www.intercell.com

This communication expressly or implicitly contains certain forward-looking
statements concerning Intercell AG and its business. Such statements involve
certain known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or achievements of
Intercell AG to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Intercell
AG is providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
[email protected]

end of announcement euro adhoc 01.07.2005 08:02:13
--------------------------------------------------------------------------------

emitter: Intercell AG
Campus Vienna Biocenter 6
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: [email protected]
WWW: www.intercell.com
ISIN: AT0000612601
indexes:
stockmarkets:
sector: Biotechnology
language: English

OTS-ORIGINALTEXT UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | OTB

print